Fortress Biotech Inc

+0.09 (+11.58%)
Products, Regulatory

Journey Medical Achieves 50% Enrollment In Phase 3 Trials Of Papulopustular Rosacea Treatment

Published: 08/30/2022 13:33 GMT
Fortress Biotech Inc (FBIO) - Journey Medical Corp Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating Dfd-29 for Treatment of Papulopustular Rosacea.
Journey Medical Corp - Co to Announce Topline Data in First Half of 2023, With a New Drug Application Subsequently Expected in Second Half of 2023.
Journey Medical Corp - After Approval, We Anticipate Dfd-29 Achieving Peak Annual Net Sales in Excess of $100 Million.
Journey Medical Corp - No Major Safety Issues Have Been Reported, and No Drug-related Serious Adverse Events Have Been Observed.